Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Market Cap	11.43B
Revenue (ttm)	2.84B
Net Income (ttm)	443.04M
Shares Out	228.81M
EPS (ttm)	1.90
PE Ratio	12.36
Forward PE	8.94
Dividend	1.30 (5.56%)
Ex-Dividend Date	Jun 17, 2025

Volume	247,500
Average Volume	309,731
Open	23.70
Previous Close	23.35
Day's Range	23.15 - 23.70
52-Week Range	21.70 - 42.95
Beta	0.44
RSI	40.43
Earnings Date	Apr 25, 2025

About HKG:6826

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel, anti-adhesion, and burn wound related products. In addition, it provides injectors, scalpels, suture needles and other products. Further, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,156
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6826

Financial Performance

In 2024, HKG:6826's revenue was 2.68 billion, an increase of 1.70% compared to the previous year's 2.63 billion. Earnings were 420.45 million, an increase of 1.04%.

Financial numbers in CNY